Back to top

Image: Bigstock

Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis

Read MoreHide Full Article

Pfizer Inc. (PFE - Free Report) announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) or eczmema in children aged three months to two years.

The steroid-free topical treatment is already approved for eczema in patients aged two years and older in the United States and Canada. The drug is also marketed in Israel and Australia under the brand name Staquis for the given patient population.

The phase IV CrisADe CARE 1 study showed that Eucrisa was well-tolerated over a four- week regimen and its safety profile was consistent with the previous clinical studies. Pfizer plans to present detail results from this label expansion study at an upcoming scientific conference.

Shares of Pfizer have inched up 0.3% so far this year, underperforming the industry’s rise of 2.1%.

 

We would like to remind investors that Pfizer added Eucrisa to its portfolio with the acquisition of Anacor Pharmaceuticals in June 2016. The company estimates Eucrisa’s peak sales potential to be at least $2 billion.

Another interesting eczema candidate in Pfizer’s portfolio is its investigational JAK1 inhibitor, abrocitinib. In May this year, the company announced that a pivotal late-stage study evaluating abrocitinib for the treatment of moderate-to-severe AD, met all the co-primary and secondary endpoints.

The phase III program (B7451012) examined two doses (100mg and 200mg once daily) of abrocitinib (PF-04965842) monotherapy in patients aged 12 and above for over 12 weeks.

Notably, many companies are developing medicines to address AD/eczema. A key new entrant in the AD market is Sanofi (SNY - Free Report) /Regeneron Pharmaceuticals’ (REGN - Free Report) Dupixent. Others also developing key immunology candidates in late-stage studies for AD include AbbVie (upadacitinib) and Lilly (LLY - Free Report) (Olumiant).

Zacks Rank

Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pfizer Inc. (PFE) - free report >>

Eli Lilly and Company (LLY) - free report >>

Sanofi (SNY) - free report >>

Regeneron Pharmaceuticals, Inc. (REGN) - free report >>